Former Procter & Gamble Vice-Chairman invests in Legacy Healthcare

Please login or
register
17.06.2020
symbolic picture botanical drug

Legacy Healthcare, a drug development biopharma company based at Biopôle close to Lausanne, with candidates in Phase III, Phase II, and marketed products, obtained the backing of Dimitri Panayotopoulos, a Swiss-based investor. His 37 years-career at Procter & Gamble culminated with the position of Vice-Chairman of all Global Business Units of P&G, overseeing $90bn in revenue.

Legacy Healthcare’s first patented drug substance is an apoptosis-modulation and anti-inflammation agent. From this drug substance, the company has developed a pipeline of innovative drugs in 4 different indications: Alopecia Areata, currently in Phase III clinical studies; Chemotherapy Alopecia, just completed Phase II, both potentially first to market in their own indication; Androgenetic Alopecia, ready to enter Phase III; and Cancer Related Fatigue, ready to enter Phase I/II.

The funds provided by Dimitri Panayotopoulos will enable accelerate the development of the drugs pipeline, in complement to the company’s revenue. The former top manager is today active as a biotech investor. After leaving P&G, he also joined the board of JBS Food, IRI, Logitech and serves as a senior advisor to the Boston Consulting Group, amongst others.

Legacy Healthcare’s drug is the first and only therapy addressing concomitantly most forms of alopecia (loss of hair caused by disease), whereas existing treatments and the ones in development target one form only, providing the company with a unique competitive edge and potential future market leader position in this multi-billion USD market.

The company’s botanical drug candidate for Alopecia Areata is finalizing Phase III trial. The initial trend in efficacy and safety of the drug candidate looks promising, although no conclusions can be made yet. The drug candidate seems to offer several potential safety and economic advantages over the investigational biologic and synthetic compounds currently being investigated in Alopecia Areata populations overall, and for children in particular.

(Press releasse / SK)

0Comments

More news about

Legacy Healthcare

Company profiles on startup.ch

Legacy Healthcare

rss